Optimization and physicochemical characterization of a triamcinolone acetonide-loaded NLC for ocular antiangiogenic applications

International Journal of Pharmaceutics

Volumn 393, Issue 1-2, 2010, Pages 168-176

  Araujo J ^a   Gonzalez Mira, E ^a   Egea, M A ^a   Garcia, M L ^a   Souto, E B ^b,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^c UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

Angiogenics; Factorial design; Nanostructured lipid carriers; NLC; Triamcinolone acetonide

Indexed keywords

NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; POLOXAMER; SQUALENE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; ACYLGLYCEROL; ANGIOGENESIS INHIBITOR; DRUG CARRIER; LIPID; NANOMATERIAL; PALMITIC ACID; POLYETHYLENE DERIVATIVE; POLYPROPYLENE; STEARIC ACID; STEARIC ACID DERIVATIVE; SURFACTANT; UCON 50 HB 5100; UCON 50-HB-5100;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DISPERSION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EYE TOXICITY; LIQUID; MALE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRESSURE; PRIORITY JOURNAL; SOLID; SURFACE PROPERTY; ANIMAL; CHEMISTRY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DOSAGE FORM; DRUG EFFECT; EYE; INFRARED SPECTROSCOPY; METHODOLOGY; PHARMACEUTICS; RAT; SCANNING ELECTRON MICROSCOPY; STATISTICAL MODEL; TOPICAL DRUG ADMINISTRATION; VASCULARIZATION; X RAY DIFFRACTION;

ADMINISTRATION, TOPICAL; ANGIOGENESIS INHIBITORS; ANIMALS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; DOSAGE FORMS; DRUG CARRIERS; DRUG COMPOUNDING; EYE; GLYCERIDES; LIPIDS; MICROSCOPY, ELECTRON, SCANNING; MODELS, STATISTICAL; NANOSTRUCTURES; PALMITIC ACID; PARTICLE SIZE; POLYETHYLENES; POLYPROPYLENES; RATS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SQUALENE; STEARIC ACIDS; SURFACE PROPERTIES; SURFACE-ACTIVE AGENTS; TECHNOLOGY, PHARMACEUTICAL; TRIAMCINOLONE ACETONIDE; X-RAY DIFFRACTION;

EID: 77953356716     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.03.034     Document Type: Article

References (46)

1. Amrite A.C., Kompella U.B. Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J. Pharm. Pharmacol. 2005, 57:1555-1563.
2. Benita S. Prevention of topical and ocular oxidative stress by positively charged submicron emulsion. Biomed. Pharmacother. 1999, 53:193-206.
3. Box, G.E.P., Hunter, W.G., Stuart Hunter, J., 1978. Statistics for Experimenters: An Introduction to Design, Data Analysis and Model Building. Wiley Series in Probability and Mathematical Statistics, John Wiley & Sons Publishers.
4. Bunjes H., Westesen K. Influences of colloidal state on physical properties of solid fats. Processes in Fats and Lipid Systems 2001, Marcel Dekker Inc., New York. K.S.E. N. Garti (Ed.).
5. Clares B., Gallardo V., Medina M.M., Ruiz M. Multilamellar liposomes of triamcinolone acetonide: preparation, stability, and characterization. J. Liposome Res. 2009, 19:197-206.
6. Conway M.D., Canakis C., Livir-Rallatos C., Peyman G.A. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J. Cataract Refract. Surg. 2003, 29:27-33.
7. Da Silva-Junior A.A., De Matos J.R., Formariz T.P., Rossanezi G., Scarpa M.V., Do Egito E.S.T., De Oliveira A.G. Thermal behavior and stability of biodegradable spray-dried microparticles containing triamcinolone. Int. J. Pharm. 2009, 368:45-55.
8. Degenring R.F., Jonas J.B. Intravitreal injection of triamcinolone acetonide as treatment for chronic uveitis. Br. J. Ophthalmol. 2003, 87:361.
9. Duvvuri S., Majumdar S., Mitra A.K. Drug delivery to the retina: challenges and opportunities. Expert Opin. Biol. Ther. 2003, 3:45-56.
10. Fang J.-Y., Fang C.-L., Liu C.-H., Su Y.-H. Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur. J. Pharm. Biopharm. 2008, 70:633-640.
11. ®) from nanospheres of biodegradable polymers. J. Control. Release 2001, 71:53-69.
12. Freitas C., Müller R.H. Correlation between long-term stability of solid lipid nanoparticles (SLN(TM)) and crystallinity of the lipid phase. Eur. J. Pharm. Biopharm. 1999, 47:125-132.
13. Hagemann J., Rothfus J. Transitions of saturated monoacid triglycerides: modeling conformational change at glycerol during α→β'→β transformation. J. Am. Oil Chem. Soc. 1993, 70:211-217.
14. Hironaka K., Inokuchi Y., Tozuka Y., Shimazawa M., Hara H., Takeuchi H. Design and evaluation of a liposomal delivery system targeting the posterior segment of the eye. J Control. Release 2009, 136:247-253.
15. Hughes P.M., Olejnik O., Chang-Lin J.E., Wilson C.G. Topical and systemic drug delivery to the posterior segments. Adv. Drug Deliv. Rev. 2005, 57:2010-2032.
16. ® ATO 5. Int. J. Pharm. 2006, 309:6-15.
17. Jonas J. Intravitreal injection of triamcinolone acetonide. Medical Retina 2005, 143-164. Springer. R.F. Spaide (Ed.).
18. Jonas J. Intravitreal triamcinolone acetonide: a change in a paradigm. Ophthalmic Res. 2006, 38:218-245.
19. Jonas J.B., Kreissig I., Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog. Retin. Eye Res. 2005, 24:587-611.
20. Kamppeter B.A., Cej A., Jonas J.B. Intraocular concentration of triamcinolone acetonide after intravitreal injection in the rabbit eye. Ophthalmology 2008, 115:1372-1375.
21. Kay J.H., Calandra J.K. Interpretation of eye irritation test. J. Soc. Cosmet. Chem. 1962, 13:281-289.
22. Keck C.M., Muller R.H. Size analysis of submicron particles by laser diffractometry - 90% of the published measurements are false. Int. J. Pharm. 2008, 355:150-163.
23. Liu W., Hu M., Liu W., Xue C., Xu H., Yang X. Investigation of the carbopol gel of solid lipid nanoparticles for the transdermal iontophoretic delivery of triamcinolone acetonide acetate. Int. J. Pharm. 2008, 364:135-141.
24. Mainardes R.M., Urban M.C., Cinto P.O., Khalil N.M., Chaud M.V., Evangelista R.C., Gremiao M.P. Colloidal carriers for ophthalmic drug delivery. Curr. Drug Targets 2005, 6:363-371.
25. Mansoor S., Kuppermann B., Kenney M. Intraocular sustained-release delivery systems for triamcinolone acetonide. Pharm. Res. 2009, 26:770-784.
26. Maurice D.M. Drug delivery to the posterior segment from drops. Surv. Ophthalmol. 2002, 47(Suppl. 1):S41-S52.
27. Mclain V.C. Safety assessment of poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, poloxamer 105 benzoate, and poloxamer 182 dibenzoate as used in cosmetics. Int. J. Toxicol. 2008, 27:93-128.
28. Müller, R.H., Lucks, J.S., 1996. Arzneistoffträger aus festen Lipidteilchen, Feste Lipid nanosphären. (SLN). European Patent EP0605497.
29. Müller R.H., Mäder K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50:161-177.
30. Müller R.H., Radtke M., Wissing S.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 2002, 54:S131-S155.
31. Nagarwal R.C., Kant S., Singh P.N., Maiti P., Pandit J.K. Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J. Control. Release 2009, 136:2-13.
32. Piermarocchi S., Sartore M., Lo Giudice G., Maritan V., Midena E., Segato T. Combination of Photodynamic Therapy and Intraocular Triamcinolone for Exudative Age-Related Macular Degeneration and Long-Term Chorioretinal Macular Atrophy. Arch. Ophthalmol. 2008, 126:1367-1374.
33. Pretsch E., Bühlmann P., Badertscher M. IR Spectroscopy. Structure Determination of Organic Compounds 2009, Springer, Berlin Heidelberg, 1-67.
34. Sahoo S.K., Dilnawaz F., Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov. Today 2008, 13:144-151.
35. Schoenwald R.B., Stewart P. Effect of particle size on ophthalmic bioavailability of dexamethasone suspensions in rabbits. J. Pharm. Sci. 1980, 69:391-394.
36. Scott I.U., Flynn H.W., Rosenfeld P.J. Intravitreal triamcinolone acetonide for idiopathic cystoid macular edema. Am. J. Ophthalmol. 2003, 136:737-739.
37. Souto E.B., Müller R.H. Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization. J. Microencapsul. 2006, 23:377-388.
38. Souto E.B., Müller R.H. Lipid nanoparticles - Effect on bioavailability and pharmacokinetics changes. Handbook of Experimental Pharmacology - Novel Drug Delivery Approaches 2009, Vol. 197:115-142. Springer Verlag, Heidelberg, Berlin, Germany, Chapter 4.
39. Souto E.B., Wissing S.A., Barbosa C.M., Müller R.H. Evaluation of the physical stability of SLN and NLC before and after incorporation into hydrogel formulations. Eur. J. Pharm. Biopharm. 2004, 58:83-90.
40. Sung P.P., Jae K.A. Changes of aqueous vascular endothelial growth factor and interleukin-6 after intravitreal triamcinolone for branch retinal vein occlusion. Clinical Exp. Ophthalm. 2008, 36:831-835.
41. Thomas M.L., Gan C.M., Polse K.A. Sequential staining: the effects of sodium fluorescein, osmolarity, and pH on human corneal epithelium. Optom. Vis. Sci. 1997, 74:207-210.
42. Tiyaboonchai W., Tungpradit W., Plianbangchang P. Formulation and characterization of curcuminoids loaded solid lipid nanoparticles. Int. J. Pharm. 2007, 337:299-306.
43. Valero J., Egea M.A., Espina M., Gamisans F., Garcia M.L. Effect of polymerization coadjuvants on nanocapsule elaboration and triamcinolone acetonide entrapment. Drug Dev. Ind. Pharm. 1996, 22:167-173.
44. Vivek K., Reddy H., Murthy R. Investigations of the effect of the lipid matrix on drug entrapment, in vitro release, and physical stability of olanzapine-loaded solid lipid nanoparticles. AAPS Pharm. Sci. Technol. 2007, 8:16-24.
45. Yang S.C., Zhu J.B. Preparation and characterization of camptothecin solid lipid nanoparticles. Drug Dev. Ind. Pharm. 2002, 28:265-274.
46. Zhang J., Fan Y., Smith E. Experimental design for the optimization of lipid nanoparticles. J. Pharm. Sci. 2009, 98:1813-1819.